Beam Therapeutics Inc.

70.89-1.80-2.48%Vol 791.88K1Y Perf 343.74%
Apr 19th, 2021 16:00 DELAYED
BID69.51 ASK73.99
Open70.70 Previous Close72.69
Pre-Market- After-Market-
 - -  - -%
Target Price
108.00 
Analyst Rating
Strong Buy 1.00
Potential %
52.35 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★+     45.35
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap4.43B 
Earnings Rating
Price Range Ratio 52W %
50.04 
Earnings Date
11th May 2021

Today's Price Range

69.7974.50

52W Range

14.80126.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.23%
1 Month
-23.68%
3 Months
-30.68%
6 Months
132.12%
1 Year
343.74%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BEAM70.89-1.8000-2.48
AAPL134.840.68000.51
GOOG2 302.404.64000.20
MSFT258.74-2.0000-0.77
XOM56.48-0.1800-0.32
WFC43.880.04000.09
JNJ162.690.45000.28
FB302.24-3.9400-1.29
GE13.460.07000.52
JPM152.65-0.6500-0.42
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.70-0.72-2.86
Q03 2020-0.57-0.69-21.05
Q02 2020-0.56-0.69-23.21
Q01 2020-0.55-1.03-87.27
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th May 2021
Estimated EPS Next Report-0.72
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume791.88K
Shares Outstanding62.47M
Trades Count15.45K
Dollar Volume150.38M
Avg. Volume1.09M
Avg. Weekly Volume855.16K
Avg. Monthly Volume982.24K
Avg. Quarterly Volume1.11M

Beam Therapeutics Inc. (NASDAQ: BEAM) stock closed at 70.89 per share at the end of the most recent trading day (a -2.48% change compared to the prior day closing price) with a volume of 793.75K shares and market capitalization of 4.43B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 166 people. Beam Therapeutics Inc. CEO is John Evans.

The one-year performance of Beam Therapeutics Inc. stock is 343.74%, while year-to-date (YTD) performance is -13.17%. BEAM stock has a five-year performance of %. Its 52-week range is between 14.8 and 126.9, which gives BEAM stock a 52-week price range ratio of 50.04%

Beam Therapeutics Inc. currently has a PE ratio of -16.90, a price-to-book (PB) ratio of 18.24, a price-to-sale (PS) ratio of 242 738.00, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -64.45%, a ROC of -67.77% and a ROE of -881.16%. The company’s profit margin is -%, its EBITDA margin is -486 883.00%, and its revenue ttm is $18.00 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Beam Therapeutics Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.72 for the next earnings report. Beam Therapeutics Inc.’s next earnings report date is 11th May 2021.

The consensus rating of Wall Street analysts for Beam Therapeutics Inc. is Strong Buy (1), with a target price of $108, which is +52.35% compared to the current price. The earnings rating for Beam Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Beam Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Beam Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 15.18, ATR14 : 9.45, CCI20 : -86.28, Chaikin Money Flow : -0.14, MACD : -7.26, Money Flow Index : 34.80, ROC : -11.43, RSI : 44.57, STOCH (14,3) : 22.57, STOCH RSI : 0.31, UO : 44.84, Williams %R : -77.43), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Beam Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (100.00 %)
4 (100.00 %)
4 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises of Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.

CEO: John Evans

Telephone: +1 857 327-8775

Address: 26 Landsdowne Street, Cambridge 02139, MA, US

Number of employees: 166

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

64%36%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

News

Stocktwits